Cardiovascular Disease Epidemiology in Patients with Lupus

项目概要/摘要 Karen Costenbader博士是一位公认的以患者为导向的流行病学和结果调查员， 系统性红斑狼疮和类风湿性关节炎，和一个非常从事下一代的导师， 以患者为导向的临床研究者。她曾担任小学或中学的研究导师40前和 博士后研究生。沿着她作为布莱根妇女医院院长的职位 Costenbader博士的指导是由她与多个哈佛大学的隶属关系促进 机构和培训计划，并与国家研究和临床组织。候选人很多 正在进行的以患者为导向的研究项目和合作，高度致力于指导和 继续提高她的指导技能，以及卓越的机构资源，为她提供了一个出色的 为初级调查员的发展创造环境。这项K24基金将保护科斯坦巴德博士的 保护她的时间，并解除她的临床和行政责任。提出了新的研究目标 将建立在过去对狼疮患者心血管疾病风险的研究基础上。数据显示， 美国有10万狼疮患者参加了医疗补助计划，新的研究将解决关键的悬而未决的问题， 关于狼疮疾病异质性和心血管疾病风险的问题，具有丰富的统计能力， 检测这些严重结果的差异。这一人群固有的社会人口变化， 在这一脆弱人群中，心血管疾病的高风险使这些研究非常相关， 改善狼疮患者的护理和预后。此外，验证和完善2017年QRISK 3 布里格姆和妇女狼疮队列中的心血管疾病风险预测算法将为患者提供 互动，以收集和验证成果，以及指导对象在制定风险预测方面的经验 算法要检查的临床问题将提供独立的项目和出版物，经验 为研究学员提供先进的生物统计模型，并提供出色的指导机会。博士 Costenbader已经组建了一支由高素质的共同导师组成的强大团队，她将招募两到三名新的导师， 她的风湿性疾病流行病学和成果研究计划每年。她将继续 利用学员的反馈和许多教育机会来完善她的指导计划和技能， 她的环境。这项K24资助将支持Costenbader博士开发下一代 以病人为导向的风湿病研究者。

PROJECT SUMMARY/ABSTRACT Dr. Karen Costenbader is a recognized patient-oriented investigator in the epidemiology and outcomes of systemic lupus erythematosus and rheumatoid arthritis, and a very engaged mentor of the next generation of patient-oriented clinical investigators. She has served as primary or secondary research mentor for 40 pre- and post-doctoral research trainees. Along with her position as Director of the Brigham and Women's Hospital Lupus Program, Dr. Costenbader's mentoring is facilitated by her affiliations with multiple Harvard-based institutions and training programs, and with national research and clinical organizations. The candidate's many ongoing patient-oriented research projects and collaborations, high degree of commitment to mentoring and to continuing to improve her mentoring skills, and the exceptional institutional resources, provide an outstanding environment for the development of junior investigators. This K24 grant would preserve Dr. Costenbader's protected time and relieve her of clinical and administrative responsibilities. The new research aims proposed will build upon past work on cardiovascular disease risk among lupus patients. With data on more than 100,000 lupus patients enrolled in Medicaid in the U.S., the new studies will address key unanswered questions about lupus disease heterogeneity and cardiovascular disease risk, with abundant statistical power to detect differences in these serious outcomes. The inherent sociodemographic variation of this population and the high risk of cardiovascular disease in this vulnerable population make these studies extremely relevant for improving care and outcomes for lupus patients. Additionally, validating and refining the 2017 QRISK3 cardiovascular disease risk prediction algorithm in the Brigham and Women's Lupus Cohort will provide patient interactions to collect and verify outcomes, and experience for mentees with developing risk prediction algorithms. The clinical questions to be examined will afford independent projects and publications, experience with advanced biostatistical models for research mentees, and excellent mentoring opportunities. Dr. Costenbader has assembled a strong team of highly qualified co-mentors and she will recruit two to three new trainees into her rheumatic disease epidemiology and outcomes research program annually. She will continue to refine her mentoring program and skills using trainee feedback and the many educational opportunities in her environment. This K24 grant would support Dr. Costenbader's ability to develop the next generation of patient-oriented rheumatic disease investigators.